-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5106 Trends in Invasive Orthopedic Interventions in Patients with Hemophilia Enrolled in the Community Counts Program (2015-2021)

Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Non-Malignant Conditions: Poster III
Hematology Disease Topics & Pathways:
Research, health outcomes research, Clinical Research, Human
Monday, December 11, 2023, 6:00 PM-8:00 PM

Daniel Isaac, DO, MSc1*, Roshni Kulkarni, MD2, Binh Le, PhD3*, Marilyn Manco-Johnson, MD4, Patricia Tobase, PT, DPT, OCS5* and Mike Soucie, PhD6,7*

1College of Human Medicine, Michigan State University, Kalamazoo, MI
2Centers for Bleeding and Clotting Disorders, Department of Pediatrics, Michigan State University, East Lansing, MI
3Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, GA
4Hemophilia & Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO
5Hemophilia Treatment Center, University of California, San Francisco, CA
6Peers & Partners, Inc; Division of Blood Disorders, Centers For Disease Control and Prevention, Atlanta, GA
7CDC, Peers & Partners, Inc, Atlanta, GA


Recurrent joint bleeding due to hemophilia often leads to the development of chronic joint disease resulting in chronic pain, decreased joint function and a significant decline in quality of life. Invasive orthopedic interventions (IOI) such as arthroplasty and arthrodesis for end stage joint disease have historically been pursued to decrease pain and improve joint function especially in patients with severe hemophilia and joint disease. Using data collected on patients receiving care in a large network of hemophilia treatment centers in the United States (USHTCN), Tobase et al have previously reported a 5.6% decline in all IOI in patients with hemophilia during the period 2000-2010 (1).


The primary objective of the current analysis was to extend those findings using similar data collected during the period 2015-2021 with a focus on IOI indicative of end stage joint disease such as arthrodesis and arthroplasty.

Data on IOI were collected annually during the period 2015–2021 from patients who participated in the Community Counts (CC) surveillance project at the 147 member USHTCN using standardized data collection tools. The proportion of patients having IOI in each year was calculated by dividing the total number of patients who reported an IOI by the total number of patients who had a CC visit in that year. Trends in proportions were plotted over time and assessed for statistical significance using the Cochran-Armitage trend test.


In total, 8,378 CC patients with a diagnosis of hemophilia A or B, over the age of 2 years who completed a subsequent CC visit within last 12 months of last surveillance visit during the years 2015–2021 were included in this study. Enrollees reported a total of 28 arthrodesis and 168 arthroplasty procedures during a total of 21,082 clinic visits over the entire study period. We found that arthroplasty represented 42.6 %, 68.8%, 17.9%, 26.3%, and 7.4% of all procedures reported in the knee, hip, ankle, shoulder, and elbow, respectively (Figure 1). The rate of IOI during the study timeframe remained very low, with only 2.4% of all participants reporting an IOI. During 2015-2021 there was a statistically significant decline in IOI among all patients >=60 years of age (0.59% in 2015 vs. 0.27% in 2021) (p=0.0325) (Figure 2). Similarly, patients with severe hemophilia regardless of age experienced a significant decline in invasive procedures during the study period (1.69% in 2015 vs. 0.88% in 2021) (p=0.021).


The rates of IOI reported during the years 2015-2021 remained very low (~2.4%). This suggests less joint morbidity and a continued decline in the rates of end stage joint disease during the study period, likely due, at least in part, to improved therapy and early adoption of preventative factor replacement protocols.


  1. Tobase P, Lane H, Siddiqi AEA, et. al. Declining trends in invasive orthopedic interventions for people with hemophilia enrolled in the Universal Data Collection program (2000-2010). Haemophilia, 2016;22(4): 604-614.

Disclosures: Manco-Johnson: Spark: Honoraria; Novo: Honoraria; Bayer: Honoraria; CSL Behring: Honoraria; Genentech: Honoraria.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH